Immunocore (NASDAQ:IMCR) Stock Price Down 2.4% - Should You Sell?

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) was down 2.4% during trading on Tuesday . The company traded as low as $27.85 and last traded at $28.71. Approximately 40,980 shares were traded during trading, a decline of 91% from the average daily volume of 438,416 shares. The stock had previously closed at $29.41.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on IMCR shares. Morgan Stanley restated an "equal weight" rating and set a $35.00 price objective on shares of Immunocore in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. Mizuho cut their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. JPMorgan Chase & Co. decreased their target price on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $71.00 target price on shares of Immunocore in a report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $60.90.

Immunocore Trading Down 0.7 %

The stock has a market cap of $1.51 billion, a P/E ratio of -31.75 and a beta of 0.75. The firm's 50 day simple moving average is $28.77 and its two-hundred day simple moving average is $30.35. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Insider Transactions at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker acquired 807,338 shares of Immunocore stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the transaction, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On Immunocore

A number of institutional investors and hedge funds have recently bought and sold shares of IMCR. GF Fund Management CO. LTD. acquired a new position in Immunocore in the fourth quarter worth approximately $25,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Immunocore in the 1st quarter worth $225,000. China Universal Asset Management Co. Ltd. raised its position in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after purchasing an additional 960 shares during the period. NEOS Investment Management LLC lifted its holdings in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after purchasing an additional 1,102 shares during the last quarter. Finally, Tema Etfs LLC acquired a new position in shares of Immunocore in the 4th quarter valued at $330,000. Institutional investors own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.